CEACAM1 and familial pancreatic carcinoma: Notably, CEACAM1, CEACAM5, and CEACAM6 have been found to be implicated in immune related disease and cancer [4–8], and are now considered valid clinical biomarkers and promising therapeutic targets in melanoma, lung, colorectal, and pancreatic cancers.